How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/blastic-phase-chronic-myeloid-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Blastic phase chronic myeloid leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blastic phase chronic myeloid leukemia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Blastic phase chronic myeloid leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Bosulif	Bosutinib Monohydrate	Pfizer	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Bosulif	bosutinib	Pfizer	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Sprycel	dasatinib	Handa Therap	dasatinib	Ephrin type-B receptor 6	2006-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Blastic phase chronic myeloid leukemia
Handa Therap · 1 drug in Blastic phase chronic myeloid leukemia
M.D. Anderson Cancer Center · 1 drug in Blastic phase chronic myeloid leukemia
Novartis · 1 drug in Blastic phase chronic myeloid leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Blastic phase chronic myeloid leukemia:

Cite this brief

Drug Landscape (2026). Blastic phase chronic myeloid leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/blastic-phase-chronic-myeloid-leukemia. Accessed 2026-06-10.

Blastic phase chronic myeloid leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing